Treatment of psoriasis in the elderly population can present many challenges to the physician. Herein we propose a treatment algorithm for psoriasis in this age group. When choosing a therapy for generalized psoriasis in elderly patients, ultraviolet treatments should be attempted first because of their efficacy and safety. Of the external treatment approaches, Goeckerman, although one of the safest and most effective therapies, should be a later treatment option, reserved for the most severe, recalcitrant cases. Acitretin is the next best approach because of its nonclinically immunosuppressive nature. If combination therapy of acitretin with phototherapy proves inadequate, etanercept, adalimumab, alefacept, ustekinumab, and infliximab should then be considered, in successive order. The penultimate treatment options to consider should be the oral agents, cyclosporine and methotrexate, because of their greater risk of major organ toxicity. The last option involves combination therapy with systemic immunosuppressant agents.
RappS.R., FeldmanS.R., ExumM.L.Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol.1999; 41: 401–7.
2.
KooJ.Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin.1996; 14: 485–96.
3.
SchönM.P., BoehnckeW.H.Psoriasis. N Engl J Med.2005; 352: 1899–912.
4.
GelfandJ.M., TroxelA B., LewisJ.D.The risk of mortality in patients with psoriasis, results from a population-based study. Arch Dermatol.2007; 143(12): 1493–9.
5.
AbuabaraK., AzfarR.S., ShinD.B.Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol.2010; 163: 586–92.
U.S. Census Bureau [online]. Available from URL: www.census.gov. Accessed 2010 Jul 26.
8.
LassilaH.C., StoehrG.P., GanguliM.Use of prescription medications in an elderly rural population: the MoVIES Project. Ann Pharmacother.1996; 30: 589–95.
9.
PilottoA., FranceschiM., LeandroM.NSAID and aspirin use by the elderly in general practice. Drugs Aging.2003; 20: 701–10.
10.
van WeeldenH., de la FailleH.B., YoungE.A new development in UVB phototherapy of psoriasis. Br J Dermatol.1988; 119: 11–9.
11.
CovenT.R., BurackL.H., GilleaudeauR.Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol.1997; 133: 1514–22.
12.
GreenC., FergusonJ., LakshmipathiT.311 nm UVB phototherapy: an effective treatment for psoriasis. Br J Dermatol.1988; 119: 691–6.
13.
FisherT.UV-light treatment of psoriasis. Acta Derm Venereol (Stockh).1976; 56: 473–9.
14.
KirkeS.M., LowderS., LloydJ.J.A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol.2007; 127: 1641–6.
15.
YonesS.S., PalmerR.A., GaribaldinosT.T.Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol.2006; 142: 836–42.
16.
van WeeldenH., de la FailleH.B., YoungE.Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol.1990; 70(3): 212–5.
17.
PittelkowM.R., PerryH.O., MullerS.A.Skin cancer in patients with psoriasis treated with coal tar: a 25-year follow-up study. Arch Dermatol.1981; 117: 465–8.
18.
HalprinK.M., ComerfordM., TaylorJ.R.Cancer in patients with psoriasis. J Am Acad Dermatol.1982; 7: 633–8.
19.
LarkoO., SwanbeckG.Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. Acta Derm Venereol Suppl (Stockh).1982; 62: 507–12.
20.
BhateS.M., SharpeG.R., MarksJ.M.Prevalence of skin and other cancers in patients with psoriasis. Clin Exp Dermatol.1993; 18: 401–4.
21.
Hannuksela-SvahnA., PukkalaE., LaaraE.Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol.2000; 114: 587–90.
22.
MaughanW.Z., MullerS.A., PerryH.O.Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. J Am Acad Dermatol.1993; 29: 1013–22.
23.
OsmancevicA., Landin-WilhelmsenK., LarköOlleRisk factors for osteoporosis and bone status in postmenopausal women with psoriasis treated with UVB therapy. Acta Derm Venereol.2008; 88: 240–6.
24.
MelskiJ.W., TanenbaumL., ParrishJ.A.Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol.1977; 68: 328–35.
25.
FisherT.Topical PUVA and bath PUVA. In: RoenigkH.H.Jr, MaibachH.I., editors. Psoriasis. 2nd ed. New York: Marcel Dekker, 1991; pp. 633–44.
26.
GordonP.M., DiffeyB.L., MatthewsJ.N.S.A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol.1999; 41(5): 728–32.
27.
SternR.S., NicholsK.T., VäkeväL.H.Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med.1997; 336(15): 1041–5.
28.
MuraseJ.E., LeeE.E., KooJ.Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol.2005; 44(12): 1016–21.
MullerS.A., PerryH.O.The Goeckerman treatment in psoriasis; six decades of experience at Mayo Clinic. Cutis.1984; 34: 265–70.
31.
LeeE., KooJ.Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatol Treat.2005; 16: 102–7.
32.
MenterA., CramD.L.The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol.1983; 9: 59–65.
33.
de MiguelR., el-AzharyR.Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. Int J Dermatol.2009; 48: 653–8.
34.
CortD.H., SchleiderN.R., MoskowitzR.S.Retrospective analysis of a modified Goeckerman regimen for the treatment of psoriasis. Cutis.1989; 25: 201–3.
35.
DesGroseilliersJ.P., CullenA.E., RouleauG.A.Ambulatory Goeckerman treatment of psoriasis: experience with 200 patients. Can Med Assoc J.1981; 124: 2018–20.
36.
RoenigkH.H.Jr, AuerbachR., MaibachH.Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol.1998; 38: 478–85.
37.
JeffesEWB3rd, McCulloughJ.L., PittelkowM.R.Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol.1995; 104(2): 183–8.
38.
HeydendaelV.M., SpulsP.I., OpmeerB.C.Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med.2003; 349: 658–65.
39.
FlytströmI., StenbergB., SvenssonÅMethotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br Assoc Dermatol.2008; 158: 116–21.
40.
BonifatiC., CarducciM., MussiA.Recognition and treatment of psoriasis: special considerations in elderly patients. Drugs Aging.1998; 12(3): 177–90.
41.
JeffesE.W.B., WeinsteinG.D.Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin.1995; 13: 875–89.
42.
MozzanicaN.Methotrexate e citostatici. Ital Gen Rev Dermatol.1994; 31: 232–41.
43.
GreavesM.W., WeinsteinG.D.Treatment of psoriasis. N Engl J Med.1995; 332: 581–8.
44.
Workshop of the Research Unit of the Royal College of Physicians of London; Departent of Dermatology, University of Glasgow; British Association of Dermatologists. Guidelines for management of patients with psoriasis. BMJ.1991; 303: 829–35.
45.
FairrisG.M., DewhurstA.G., WhiteJ.W.Methotrexate dosage in patients aged over 50 with psoriasis. BMJ.1989; 298: 801–2.
46.
GrossmanR.Ciclosporina. In: DubertretL. editor. Psoriasi.Brescia (Italy): ISED; 1993: pp. 174–85.
47.
WongR.L., WinslowC.M., CooperK.D.The mechanisms of action of ciclosporin A in the treatment of psoriasis. Immunol Today.1993; 14: 69–74.
48.
KooJ.A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmune in patients with severe psoriasis. Br J Dermatol.1998; 139: 88–95.
49.
OzawaA., SugaiJ., OhkidoM.Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy. Eur J Dermatol.1999; 9(3): 218–23.
HoV.C.The use of cyclosporine in psoriasis: a clinical review. Br J Dermatol.2004; 150(suppl 67): 1–10.
52.
GriffithsC.E.M., DubertretL., EllisC.N.Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol.2004; 150: 11–23.
53.
PaulC.F., HoV.C., McGeownC.Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol.2003; 120: 211–6.
54.
Della Casa-AlberighiO.Ciclosporina. Ital Gen Rev Dermatol.1994; 31: 241–63.
55.
KooJ., LeeJ.Cyclosporine: what clinicians need to know. Dermatol Clin.1995; 13: 897–907.
56.
GollnickH., BauerR., BrindleyC.Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol.1988; 19: 458–69.
57.
KragballeK., JansenC.T., GeigerJ.M.A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol.1989; 69: 35–40.
58.
YamauchiP.S., RizkD., KormeiliT.Current systemic treatments for psoriasis: where are we now?J Am Acad Dermatol.2003; 49: 66–77.
BhutaniT., KooJ.A review of the chemopreventative effects of oral retinoids for internal neoplasms. J Drugs Dermatol; in press.
61.
Hernandez-PerezE., KhawajaH.A., AlvarezT.Y.Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol Surg.2000; 26(7): 649–52.
62.
GlaserD.A., RogersC.Topical and systemic therapies for the aging face. Facial Plast Surg Clin N Am.2001; 9(2): 189–96.
63.
PappK.A., TyringS., LahfaM.A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol.2005; 152: 1304–12.
64.
MilitelloG., XiaA., StevensS.R.Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol.2006; 55: 517–9.
65.
GottliebA.B., LeonardiC.L., GoffeB.S.Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol.2006; 54(3 Suppl 2): S92–100.
66.
WeinbergJ.M., SainiR.Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Cutis.2003; 71: 25–9.
67.
CalabreseL.H.Molecular differences in anticytokine therapies. Clin Exp Rheumatol.2003; 21: 241–8.
68.
MenterA., GordonK.B., LeonardiC.L.Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol.2010; 2010: 63(3): 448–6.
69.
MenterA., TyringS.K., GordonK.Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol.2008; 58: 1006–15.
70.
DixonW.G., HyrichK.L., WatsonK.D.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis.2010; 69: 522–8.
71.
TubachF., SalmonD., RavaudP.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arthritis Rheum.2009; 60(7): 1884–94.
72.
MMWR Weekly, March 20, 2009; 58(10): 249–253.
73.
PerlmutterA., CatherJ., FranksB.Alefacept revisited: our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol.2008; 58(1): 116–24.
74.
LebwohlM., ChristophersE., LangleyR.An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol.2003; 139: 719–27.
75.
KruegerG.G., PappK.A., StoughD.B.A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol.2002; 47: 821–33.
76.
GottliebA.B., BoehnckeW.H., DarifM.Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol.2005; 4(6): 718–24.
77.
LoweN.J., GonzalesJ., BagelJ.Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol.2003; 42(3): 224–30.
78.
GriffithsC.E.M., StroberB.E., van de KerkhofP.Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med.2010; 362(2): 118–28.
79.
JesitusJ.CV alert: new data raises concern over biologics targeting IL-12/23 pathway. Dermatol Times.2010; 31: 5–7.
80.
LeonardiC.L., KimballA.B., PappK.A.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with Psoriasis: 76 week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)Lancet.2008; 371(9625): 1665–74.
81.
ScanlonJ.V., ExterB.P., SteinbergM.Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother.2009; 43: 1456–65.
82.
KimbellA., GoeffeB., BissonnetteR.Efficacy of ustekinumab is sustained through 3 years of treatment for patients with moderate-to-severe psoriasis maintained on q12 week dosing based on body weight [poster].American Academy of Dermatololgy, August 4–8, 2010. Chicago, IL.
83.
GordonK., LeonardiC., LebwohlM.The ustekinumab safety experience in patients with moderate-to-severe psoriasis: results from pooled analysis of phase 2 and phase 3 clinical trial data [poster].European Academy of Dermatology and Venereology, October 7–11, 2009. Berlin, Germany.
84.
GoedkoopA.Y., KraanM.C., TeunissenM.B.M.Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis.2004; 63: 769–73.
85.
GottliebA.B., EvansR., LiS.Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol.2004; 51: 534–42.
86.
ReichK., NestleF.O., PappK.Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet.2005; 366: 1367–74.
87.
MenterA., FeldmanS.R., WeinsteinG.D.A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol.2007; 56: 31.e1–15.
88.
MenterA., GottliebA.B., FeldmanS.R.Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol.2008; 58(5): 826–50.
89.
McElhaneyJ.E., EffrosR.B.Immunosenescence: what does it mean to health outcomes in older patients?Curr Opin Immunol.2009; 21: 418–24.
90.
CallenJ.P.Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg.2007; 26: 6–14.
91.
HaitzK.A., KalbR.E.Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol.2207; 57: 120–5.
92.
ShearN.H.Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability?Drug Saf.2006; 29: 49–66.
93.
LoweN.J., PrystowskyJ.H., BourgetT., EdelsteinJ., NychayS., ArmstrongR.Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol.1991; 24(4): 591–4.
94.
RuzickaT., SommerburgC., Braun-FalcoO.Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol.1990; 126(4): 482–6.
95.
IestJ., BoerJ.Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol.1989; 120(5): 665–70.
96.
TanewA., GuggenbichlerA., HönigsmannH., GeigerJ.M., FritschP.Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol.1991; 25(4): 682–4.
